Patients at lower risk of arrhythmia recurrence: A subgroup in whom implantable defibrillators may not offer benefit

被引:39
作者
Hallstrom, AP
McAnulty, JH
Wilkoff, BL
Follmann, D
Raitt, MH
Carlson, MD
Gillis, AM
Shih, HT
Powell, JL
Duff, H
Halperin, BD
机构
[1] Univ Washington, Seattle, WA 98105 USA
[2] Oregon Hlth & Sci Univ, Collaborating Med Ctr, Portland, OR 97201 USA
[3] Univ Hosp Cleveland, Cleveland, OH 44106 USA
[4] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[5] Univ Texas, Sch Med, Houston, TX USA
[6] Univ Calgary, Calgary Reg Hlth Author Hosp, Calgary, AB, Canada
关键词
D O I
10.1016/S0735-1097(00)01208-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES The goal of this study was to identify subgroups of arrhythmia patients who do not benefit from use of the implantable cardiac defibrillator (ICD). BACKGROUND Treatment of serious ventricular arrhythmias has evolved toward more common use of the ICD. Since estimates of the cost per year of life saved by ICD therapy vary from $25,000 to perhaps $125,000, it is important to identify patient subgroups that do not benefit from the ICD. METHODS Data for 491 ICD patients enrolled in the Antiarrhythmics Versus Implantable Defibrillators Study were used to create a hazards model relating baseline factors to time to first recurrent arrhythmia. The model was used to predict the hazard for recurrent arrhythmia among all trial patients. A priori cut points provided lower and higher recurrent arrhythmia risk strata. For each stratum the incremental years of life due to ICD versus antiarrhythmic drug therapy were calculated. RESULTS Factors that predicted recurrent arrhythmia were: ventricular tachycardia as the index arrhythmia, history of cerebrovascular disease, lower left ventricular ejection fraction, a history of any tachyarrhythmia before the index event and the absence of revascularization after the index event. Survival times (over a follow-up of three years) were identical in each arm of the lowest risk sextile (survival advantage 0.03 +/- 0.12 [se] years), while the survival advantage for patients above the first sextile was 0.27 +/- 0.07 (se) pears (two-sided p = 0.05). CONCLUSIONS Patients presenting with an isolated episode of ventricular fibrillation in the absence of cerebrovascular disease or history of prior arrhythmia who have undergone revascularization or who have moderately preserved left ventricular function (left ventricular ejection fraction > 0.27) are not likely to benefit from ICD therapy compared with amiodarone therapy. (J Coll Cardiol 2001;37:1093-9) (C) 2001 by the American College of Cardiology.
引用
收藏
页码:1093 / 1099
页数:7
相关论文
共 9 条
  • [1] *ANT VERS IMPL DEF, 1997, NEW ENGL J MED, V33, P1576
  • [2] Canadian implantable defibrillator study (CIDS) - A randomized trial of the implantable cardioverter defibrillator against amiodarone
    Connolly, SJ
    Gent, M
    Roberts, RS
    Dorian, P
    Roy, D
    Sheldon, RS
    Mitchell, LB
    Green, MS
    Klein, GJ
    O'Brien, B
    [J]. CIRCULATION, 2000, 101 (11) : 1297 - 1302
  • [3] Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias
    Domanski, MJ
    Sakseena, S
    Epstein, AE
    Hallstrom, AP
    Brodsky, MA
    Kim, S
    Lancaster, S
    Schron, E
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 34 (04) : 1090 - 1095
  • [4] GREENE HL, 1999, J AM COLL CARDIOL, V34, P1552
  • [5] Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest -: The Cardiac Arrest Study Hamburg (CASH)
    Kuck, KH
    Cappato, R
    Siebels, J
    Rüppel, R
    [J]. CIRCULATION, 2000, 102 (07) : 748 - 754
  • [6] LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473
  • [7] Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia
    Moss, AJ
    Hall, WJ
    Cannom, DS
    Daubert, JP
    Higgins, SL
    Klein, H
    Levine, JH
    Saksena, S
    Waldo, AL
    Wilber, D
    Brown, MW
    Heo, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) : 1933 - 1940
  • [8] The cost-effectiveness of automatic implantable cardiac defibrillators: Results from MADIT
    Mushlin, AI
    Hall, WJ
    Zwanziger, J
    Gajary, E
    Andrews, M
    Marron, R
    Zou, KH
    Moss, AJ
    [J]. CIRCULATION, 1998, 97 (21) : 2129 - 2135
  • [9] Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death
    Owens, DK
    Sanders, GD
    Harris, RA
    McDonald, KM
    Heidenreich, PA
    Dembitzer, AD
    Hlatky, MA
    [J]. ANNALS OF INTERNAL MEDICINE, 1997, 126 (01) : 1 - 12